DJIA 16,408.54 -16.31 -0.10%
NASDAQ 4,095.52 9.29 0.23%
S&P 500 1,864.85 2.54 0.14%
market minute promo

company name or ticker

Infinity Pharmaceuticals Enters Oversold Territory (INFI)

Commit To Purchase Infinity Pharmaceuticals At $10, Earn 13.5% Annualized Using Options

Infinity Pharma Rises on Narrower-than-Expected Loss - Analyst Blog

Infinity Pharmaceuticals (INFI) Jumps: Stock Adds 15.5% in Session - Tale of the Tape

Why InterMune, Zulily, and Infinity Pharmaceuticals Are Today's 3 Best Stocks

Economic data pushes the S&P 500 marginally lower as InterMune, Zulily, and Infinity Pharmaceuticals all exploded higher.

Why Infinity Pharmaceuticals Inc. Shares Jumped

Shares of Infinity Pharmaceuticals jump by double-digits after reporting its fourth-quarter earnings results. Find out why investors would be wise to overlook the headline number and focus on this figure instead.

Infinity Pharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript

The Hidden Gems in Gilead Sciences' Pipeline

Gilead investors should look beyond the company’s antiviral portfolio and take a closer look at these hidden gems in its pipeline, which could shape the company’s long-term future.

The Billion-Dollar Biotech Club: Speculation Trumped Risk

Synta Pharmaceuticals: 4 Key Investing Takeaways From 2013

Let’s take a look at 4 key investing takeaways from Synta’s volatile year, and how larger companies, like Infinity Pharmaceuticals, Roche, and GlaxoSmithKline, fit into the company’s growth prospects for 2014.
See More Articles...